Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Frontier Medicines

Frontier Medicines to Participate in Two Upcoming March Investor Conferences
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines to Participate in Upcoming Investor Conferences
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
From Frontier Medicines
Via GlobeNewswire
Tickers GLPG
Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors
From Frontier Medicines
Via GlobeNewswire
Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference
From Frontier Medicines
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.